Symbiotix Biotherapies Raises Equity Round from Kairos Ventures

Choate recently represented Symbiotix Biotherapies, Inc. (Symbiotix), a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome, in its recent equity financing from Kairos Ventures, LLC.

Symbiotix is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. Symbiotix is developing a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiome.

Choate has represented Symbiotix since its formation. The transactional team was led by Brian Goldstein and Tobin Sullivan and ongoing IP strategy for the company has been led by Dr. Brenda Herschbach Jarrell.